Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or

Athenex Inc (ATNX)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 938,924
  • Shares Outstanding, K 67,066
  • Annual Sales, $ 89,100 K
  • Annual Income, $ -117,440 K
  • 60-Month Beta 0.03
  • Price/Sales 10.42
  • Price/Cash Flow N/A
  • Price/Book 9.71

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 4 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/19
See More
  • Average Estimate -0.44
  • Number of Estimates 2
  • High Estimate -0.40
  • Low Estimate -0.47
  • Prior Year -0.58
  • Growth Rate Est. (year over year) +24.14%

Price Performance

See More
Period Period Low Period High Performance
1-Month
9.38 +49.25%
on 05/01/19
14.75 -5.08%
on 05/13/19
+3.24 (+30.11%)
since 04/24/19
3-Month
9.38 +49.25%
on 05/01/19
14.75 -5.08%
on 05/13/19
+0.88 (+6.71%)
since 02/22/19
52-Week
9.38 +49.25%
on 05/01/19
20.90 -33.01%
on 07/26/18
-2.60 (-15.66%)
since 05/24/18

Most Recent Stories

More News
Athenex: 1Q Earnings Snapshot

BUFFALO, N.Y. (AP) _ Athenex Inc. (ATNX) on Thursday reported a loss of $35.2 million in its first quarter.

ATNX : 14.00 (+1.16%)
Athenex, Inc. Announces First Quarter 2019 Financial Results and Provides Corporate Update

Positive Phase 3 data for KX2-391 featured at 2019 AAD Annual Meeting

ATNX : 14.00 (+1.16%)
Biotech Stocks: Why Expensive U.S. Drug Trials are Pushing Pharma Research Overseas

Financialnewsmedia.com News Commentary

ESPR : 52.33 (+2.71%)
ATNX : 14.00 (+1.16%)
TXMD : 3.18 (+3.25%)
ZYNE : 13.18 (-2.59%)
Athenex Announces $100 Million Private Placement

Athenex, Inc. (Nasdaq: ATNX), a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies for the treatment of cancer and related conditions, today...

ATNX : 14.00 (+1.16%)
Athenex Announces Promising Early and Complete Response Data from a Clinical Study of Oraxol in Cutaneous Angiosarcoma

Athenex, Inc. (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies for the treatment of cancer and related conditions, today...

ATNX : 14.00 (+1.16%)
Athenex Announces Abstracts Accepted for Presentation at the 2019 American Society of Clinical Oncology Annual Meeting

Athenex, Inc. (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies for the treatment of cancer and related conditions, today...

ATNX : 14.00 (+1.16%)
Athenex Announces Appointment of John Koh as a New Board Member

Athenex, Inc. (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies for the treatment of cancer and related conditions, today...

ATNX : 14.00 (+1.16%)
Athenex Announces Appointment of Jordan S. Kanfer to Board of Directors

Athenex, Inc. (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies for the treatment of cancer and related conditions, today...

ATNX : 14.00 (+1.16%)
Athenex Announces Appointment of Dr. Daniel Von Hoff as Chairman of the Scientific Advisory Board of Axis Therapeutics Limited

Athenex, Inc. (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies for the treatment of cancer and related conditions, today...

ATNX : 14.00 (+1.16%)
New Research Coverage Highlights UnitedHealth Group, Ultragenyx Pharmaceutical, Navistar International, REGENXBIO, Par Pacific, and Athenex -- Consolidated Revenues, Company Growth, and Expectations for 2019

In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of UnitedHealth Group Incorporated...

NAV : 30.85 (+0.62%)
ATNX : 14.00 (+1.16%)
RARE : 57.18 (+0.97%)
PARR : 19.50 (+0.31%)
RGNX : 45.64 (+7.44%)
UNH : 247.63 (+0.46%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 80% Buy with a Average short term outlook on maintaining the current direction.

Longer term, the trend strength is Strong. Long term indicators fully support a continuation of the trend.

See More Share

Trade ATNX with:

Business Summary

Athenex, Inc. is a clinical stage biopharmaceutical company. It engaged in the discovery and development of drugs for the treatment of cancer. The company's platform including an Oncology Innovation Platform, a Commercial Platform and a Global Supply Chain Platform. It operates primarily in Buffalo and...

See More

Key Turning Points

2nd Resistance Point 14.37
1st Resistance Point 14.18
Last Price 14.00
1st Support Level 13.70
2nd Support Level 13.41

See More

52-Week High 20.90
Fibonacci 61.8% 16.50
Fibonacci 50% 15.14
Last Price 14.00
Fibonacci 38.2% 13.78
52-Week Low 9.38

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar